This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sever, P. Search for Related Content PubMed PubMed Citation Articles by Sever, P. Pubmed/NCBI databases Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Social Bookmarking                         What's this?

ALLHAT: definitive answers or continuing uncertainty?

Imperial College London, NHLI Division, Department of Clinical Pharmacology, QEQM Wing, St Mary's Hospital, London, W2 1NY, UK, p.sever{at}ic.ac.uk

Key Words: hypertension • clinical trial • lipid lowering • mortality

References

• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002;23:2981-97.
• Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of mild hypertension study: final results: Treatment of Mild Hypertension Study Research Group. JAMA 1993;270:713-24.[Abstract/Free Full Text]
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major cardiovascular events in hypertensive patients randomised to doxazosin vs. chlorthalidone. JAMA 2000;283:1957-75.[Free Full Text]
• Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Neal B., MacMahon S., Chapman N for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.overviews of ran[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sever PS, Dahlof B., Poulter NR et al. Rationale, design, methods, and baseline demography of participants of the Anglo-S Scandinavian Cardiac Outcomes Trial. J Hypertens 2002; 19:1139-47.[CrossRef][Web of Science]
• Mann J., Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-83.
• Psaty BM, Heckbert SR, Koepsell TD et al. The risk of MI associated with antihypertensive drug therapies. JAMA 1995; 274:620-5.[Abstract/Free Full Text]
• Heart Outcomes Prevention (HOPE) Study Investigators. Effect of ramipril on cardiovascular and microvascular outIcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Williams B. The renin angiotensin system and cardiovascular disease: hope or hype? JRAAS 2000;1:142-6.[Medline] [Order article via Infotrieve]
• Poulter N., Williams B. Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. Letter to the Editor. Am J Hypertens 2001;14:1170-1.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Chalmers J. All hats off to ALLHAT: a massive study with clear messages. J Hypertens 2003;21:225-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fagard RH The ALLHAT trial: strengths and limitations. J Hypertens 2003;21:229-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kaplan NM The meaning of ALLHAT. J Hypertens 2003; 21:233-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Multiple risk factor intervention trial research group - mortality rates after 10.5 years for participants in the multiple risk factor intervention trial. JAMA 1990;263:1795-801.[Abstract/Free Full Text]
• Brown MJ, Palmer CR, Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker of diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs. usual care. JAMA 2002;288:2998-3007.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 1, 3-5 (2003)
DOI: 10.3317/jraas.2003.004


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sever, P. Search for Related Content PubMed PubMed Citation Articles by Sever, P. Pubmed/NCBI databases Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Social Bookmarking                         What's this?